Hongyan Liang, MD
Hematology & Oncology · Pennington, NJNPI 1194931568
Payments from drug & device makers
Across 119 payments — averaging $541.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$47K
- Takeda Pharmaceuticals U.S.A., Inc.$15K
- AstraZeneca$279
- Daiichi Sankyo Inc.$182
- Sanofi$180
- E.r. Squibb & Sons, L.L.C.$152
- plus $1K from 32 others
What the payments were for
- Food & beverage$2,18294%
- Education$1426%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 5 | $46,965 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $15,182 |
| AstraZeneca(2 entities) | 10 | $279 |
| Daiichi Sankyo Inc. | 9 | $182 |
| Sanofi | 9 | $180 |
| E.r. Squibb & Sons, L.L.C. | 9 | $152 |
| Novartis | 7 | $141 |
| Myriad Genetic Laboratories, Inc. | 4 | $122 |
| Gilead | 1 | $96 |
| Bayer | 5 | $89 |
| Eisai Inc. | 4 | $72 |
| Amgen | 4 | $71 |
| AbbVie | 4 | $68 |
| Pfizer | 4 | $63 |
| Array Biopharma Inc | 3 | $63 |
| Stemline Therapeutics Inc. | 3 | $62 |
| Ipsen Biopharmaceuticals, Inc | 3 | $56 |
| Regeneron Healthcare Solutions, Inc. | 3 | $53 |
| Incyte Corporation | 3 | $49 |
| Lilly USA, LLC | 3 | $45 |
| Octapharma USA, Inc. | 1 | $38 |
| GSK | 2 | $38 |
| Johnson & Johnson(2 entities) | 2 | $34 |
| Genmab U.S., Inc. | 2 | $33 |
| Taiho Oncology, Inc. | 2 | $33 |
| Puma Biotechnology, Inc. | 2 | $29 |
| AVEO Pharmaceuticals, Inc. | 1 | $26 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $23 |
| Pharmacosmos Therapeutics Inc. | 1 | $19 |
| Beone Medicines USA, Inc. | 1 | $19 |
| Sobi, Inc | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Servier Pharmaceuticals LLC | 1 | $15 |
| Bristol Myers Squibb | 1 | $15 |
| Mirati Therapeutics, Inc. | 1 | $15 |
| Foundation Medicine, Inc. | 1 | $15 |
| Morphosys, US Inc. | 1 | $14 |
How this compares
$64,404 in reported general payments places this provider in the 75th percentile of 362 hematology & oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 72 | $1,129,062 |
| JakafiRuxolitinib Phosphate | 13 | $256,478 |
| TasignaNilotinib Hcl | 13 | $224,768 |
| SprycelDasatinib | 11 | $189,752 |
| EliquisApixaban | 141 | $113,844 |
| CreonLipase/Protease/Amylase | 18 | $74,506 |
| XareltoRivaroxaban | 29 | $35,935 |
| Anastrozole | 40 | $904 |
| Hydroxyurea | 38 | $759 |
| Oxycodone Hcl | 34 | $682 |
| ValacyclovirValacyclovir Hcl | 12 | $487 |
| Ondansetron OdtOndansetron | 20 | $464 |
| Warfarin Sodium | 18 | $243 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 14 | $239 |
| Ondansetron Hcl | 24 | $175 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $15 | $1,129,06272 claims |
| Incyte CorporationJakafi | $49 | $256,47813 claims |
| NovartisTasigna | $141 | $224,76813 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $152 | $189,75211 claims |
| PfizerEliquis | $63 | $113,844141 claims |
| AbbVieCreon | $68 | $74,50618 claims |
| Johnson & JohnsonXarelto | $34 | $35,93529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 362 hematology & oncology providers in New Jersey.
Other hematology & oncology in Pennington
- Pamela CrilleyPennington$941K
- Arturo Loaiza-BonillaPennington$871K
- Bruno FangEast Brunswick$8.5M
- Charles FarberMorristown$4.6M
- Rajat BannerjiNew Brunswick$3.3M
- Eleonora TeplinskyParamus$2.6M
- Mohamad CherryMorristown$1.9M
- Evan NaylorManahawkin$1.3M
- James OrsiniBelleville$1.3M
- Eli KirshnerWestwood$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.